

KASBP-SF 2021 eSYMPOSIUM

February 4-5 2021 5-9pm PST
February 5-6 2021 10-2pm KST

Registration: <https://www.kasbpsf.org>

Drug Discovery and Development



The Role of
Clinical
Pharmacology
Modelling and
Simulation in
Drug
Development

Joseph Kim
Parexel



Discovery of
AMG 510,
a first-in-human
covalent inhibitor
of KRAS^{G12C} for
the treatment
of solid tumors

Young Sook Shin
Kanaph Therapeutics



Development
of novel
platform
technologies
for CNS
therapeutics

Han-Joo Kim
IMNEWRUN Biosciences

Business Development



IB's Perspective
on Facilitating
BD Transactions

Ted Moon
RM Global Partners



Accelerating
Innovation
and Capturing
Value in the
Asia Pacific

Stephen Lee
Johnson & Johnson



Business
Development
and Open
Innovation
at Yuhan


Taejin Yoon
Yuhan

Innovative Start-ups



How can the marriage of
cancer organoids and
CRISPR open the door
for novel cancer
immunotherapies
for solid tumors?

Kyuho Han
MEDIC Life Sciences



InfoBoss pipeline for
developing new drugs from
biological big data with
AI-based genome
analysis pipeline

Jongsun Park
InfoBoss



Building a good-to-great
start-up with
financial partners

Ahryon Cho
Mirae Asset Venture Investment



Financing trend and
outlook in Korean Biotech
and Life Sciences sector

Seyoung Moon
ES Investor

KASBP-SF 2021 eSYMPOSIUM SPONSORS



SYMPOSIUM SCHEDULE TABLE (US PST)

	February 4, Thursday	February 5, Friday
Feb 4 - 5 5:00 PM– 9:00 PM (US PST) 8:00 PM– 12:00 AM (US EST)	5:00 – 5:15 PM Opening and Congratulatory Remarks	5:00 – 6:40 PM Session 2: Business Development
	KASBP-SF President: Hanjo Lim	Ted Moon <i>RM Global Partners</i>
	KASBP President: Soo-Hee Park	Stephen Lee <i>Johnson & Johnson</i>
		Taejin Yoon <i>Yuhan</i>
	5:15 – 7:15 PM Session 1: Durg Discovery & Development	
	Joseph Kim, <i>Parexel</i>	6:40 – 7:10 PM Sponsor Presentation II
	Young Sook Shin <i>Kanaph Therapeutics</i>	Hanmi Pharmaceutical
	Han-Joo Kim <i>IMNEWRUN Biosciences</i>	Bridge Bio
	7:15 – 7:25 PM Break	7:10 – 7:20 PM Break
	7:25 – 8:10 PM Sponsor Presentation I	7:20 – 9:00 PM Session 3: Innovative Start-ups
	GC LabCell	Kyuho Han <i>MEDIC Life Sciences</i>
	ST Pharm	Jongsun Park <i>InfoBoss</i>
	KEIT	Ahryon Cho <i>Mirae Asset Venture Investment</i>
	Seyoung Moon <i>ES Investor</i>	
8:10 – 9:00 PM Networking & Career session		

SYMPOSIUM SCHEDULE TABLE (KST)

	February 5, Friday	February 6, Saturday
Feb 5 - 6 10:00 AM -2:00 PM (KST)	10:00 – 10:15 AM Opening and Congratulatory Remarks	10:00 – 11:40 PM Session 2: Business Development
	KASBP-SF President: Hanjo Lim	Ted Moon <i>RM Global Partners</i>
	KASBP President: Soo-Hee Park	Stephen Lee <i>Johnson & Johnson</i>
		Taejin Yoon <i>Yuhan</i>
	10:15 – 12:15 PM Session 1: Durg Discovery & Development	
	Joseph Kim, <i>Parexel</i>	11:40 – 12:10 PM Sponsor Presentation II
	Young Sook Shin <i>Kanaph Therapeutics</i>	Hanmi Pharmaceutical
	Han-Joo Kim <i>IMNEWRUN Biosciences</i>	Bridge Bio
	12:15 – 12:25 PM Break	12:10 – 12:20 PM Break
	12:25 – 1:10 PM Sponsor Presentation I	12:20 – 2:00 PM Session 3: Innovative Start-ups
	GC LabCell	Kyuho Han <i>MEDIC Life Sciences</i>
	ST Pharm	Jongsun Park <i>InfoBoss</i>
	KEIT	Ahryon Cho <i>Mirae Asset Venture Investment</i>
	Seyoung Moon <i>ES Investor</i>	
1:10 – 2:00 PM Networking & Career session		

SYMPOSIUM SCHEDULE IN DETAIL

February 2, 2021, Tuesday – February 3, 2021, Wednesday

Job Fair

February 4, 2021, Thursday

5:00 – 5:15 PM	Opening and Congratulatory Remarks	<i>Moderator: Sehyun Kim (KASBP-SF President Designated, ABL Bio)</i>
	Opening Remark	<i>Hanjo Lim (KASBP-SF President, Genentech)</i>
	Congratulatory Remark	<i>Soo-Hee Park (KASBP President, Novartis)</i>

Session 1: Drug Discovery & Development

Moderator: Gayoung Jeong (1st Vice President, Bristol Myers Squibb)

5:15 – 5:55 PM	The Role of Clinical Pharmacology Modelling and Simulation in Drug Development	<i>Joseph Kim (Parexel)</i>
5:55 – 6:35 PM	Discovery of AMG 510, a first-in-human covalent inhibitor of KRAS ^{G12C} for the treatment of solid tumors	<i>Young Sook Shin (Kanaph Therapeutics)</i>
6:35 – 7:15 PM	Development of novel platform technologies for CNS therapeutics	<i>Han-Joo Kim (IMNEWRUN Biosciences)</i>
7:15 – 7:25 PM	Break	

Sponsor Presentation I

Moderator: Dongkyoon Kim (Science Director, Atreca)

7:25 – 7:40 PM	GC LabCell	<i>Yu-Kyeong Hwang (SVP, Head of R&D/GC LabCell Cell Therapy Research Center)</i>
7:40 – 7:55 PM	ST Pharm	<i>Hyun Min Lee (VP)</i>
7:55 – 8:10 PM	KEIT (한국산업기술평가원)	<i>Sangho Lee (PD), Jihoon Park (PD)</i>

8:10 PM **Networking & Career session**

A: Business/Operations
A-1: BD Licensing

Moderator: Sehyun Kim (ABL Bio)

KASBP-SF 2021 eSYMPOSIUM PROGRAM

A-2: Clinical	<i>Moderator: Hanna Cho (BioMarin)</i>
B: Discovery Biology	
B-1: Onco-immunology	<i>Moderator: Jihoon Chang (Kanaph)</i>
B-2: Other biology	<i>Moderator: Hyunsun Jo (PIN Therapeutics)</i>
B-3: Biomarker discovery	<i>Moderator: Yisun Kim (Genentech)</i>
C: Data Science	<i>Moderator: Meena Choi (Genentech)</i>
D: Dev Sci (CMC, analytical)	<i>Moderator: Jeongsup Shim (Genentech)</i>
E: Med chem	<i>Moderator: Joon Won Jeong/Seounghoon Ma (Exelixis)</i>
F: Career development	<i>Moderator: Gyu Seok Baik (CurioChips)</i>

SYMPOSIUM SCHEDULE IN DETAIL

February 5, 2021, Friday

Session 2: Business Development

Moderator: Sehyun Kim (KASBP-SF President Designated, ABL Bio)

5:00 – 5:20 PM IB's Perspective on Facilitating BD Transactions

Ted Moon (RM Global Partners)

5:20 – 5:40 PM Accelerating Innovation and Capturing Value in the Asia Pacific

Stephen Lee (Johnson & Johnson)

5:40 – 6:00 PM Business Development and Open Innovation at Yuhan

Taejin Yoon (Yuhan)

6:00 – 6:40 PM Panel discussion

Sponsor Presentation II

Moderator: Seungbum Kim (Public Relations Director, Acceleron Pharma)

6:40 – 6:55 PM Hanmi Pharmaceutical

Lauren Young-Mi Lee (SVP, Head of Global R&D Innovation)

6:55 – 7:10 PM BridgeBio

Gwang Hee Lee (VP, Head of Research)

7:10 – 7:20 PM Break

Session 3: Innovative Start-ups

Moderator: Hyunyong Jin (Membership Director, Genentech)

7:20 – 7:40 PM How can the marriage of cancer organoids and CRISPR open the door for novel cancer immunotherapies for solid tumors?

Kyuhoo Han (MEDIC Life Sciences)

7:40 – 8:00 PM InfoBoss pipeline for developing new drugs from biological big data with AI-based genome analysis pipeline

Jongsun Park (InfoBoss)

8:00 – 8:15 PM Building a good-to-great start-up with financial partners

Ahryon Cho (Mirae Asset Venture Investment)

8:15 – 8:30 PM Financing trend and outlook in Korean Biotech and Life Sciences sector

Seyoung Moon (ES Investor)

8:30 – 9:00 PM Panel discussion

KASBP-SF 2021 eSYMPOSIUM PROGRAM

9:00 PM

Closing remarks

*Hanjo Lim (KASBP-SF President,
Genentech)*

SPEAKERS



Joseph Yong Ho Kim, Ph.D., RPh
*Vice President, Clinical Pharmacology Modelling
and Simulation, Parexel*

Bio-sketch

- >20 years clinical drug development experience in industry
- Drug development consultant, focus on PK, PK/PD modeling application. Experienced with NONMEM, WinNonlin, Trial Simulator, R, S+
- Has provided diverse PK and PK/PD modeling and simulation support for numerous clinical studies including FTIH, POC, DDI, POP PK, pediatric and BA/BE studies and more.
- Extensive experience with small and large molecule, including biosimilar
- Broad regulatory agency interactions with FDA/EMA and other international agencies such as KFDA/CFDA

Abstract

In drug development process, clinical pharmacology studies contribute more than 60% of drug labeling information and the cost of doing clinical studies are increasing exponentially. The knowledge and skills of clinical pharmacologists are diverse and require deep understanding of pharmacokinetics (PK), pharmacodynamics (PD), drug metabolism and overall drug development. Especially, the application of clinical pharmacology modelling and simulations (CPMS) has been growing in clinical drug development not only within large pharmaceutical companies but also small biotech companies as well.

In this presentation, the overall drug development process will be briefly introduced and the role and use of modeling and simulation (M&S) will be presented with real cases in different phases of clinical drug development including the application of M&S for dose selection, study design, and the internal team and regulatory (e.g. FDA, EMA) interactions. The importance and added value of clinical pharmacology, PK, PK/PD M&S will be discussed.

SPEAKERS

Young Sook Shin, Ph.D.
Executive Vice president, Kanaph Therapeutics

Bio-sketch

- 20+ years of experience in the biotechnology and pharmaceutical industry as a medicinal chemist, working on very diverse small molecule drug discovery projects targeting inflammation, diabetes, obesity, and oncology, and directly contributed to the advancement of three small molecules to human clinical trials, most recently AMG 510 (covalent inhibitor of KRAS^{G12C} for the treatment of solid tumors).
- Kanaph Therapeutics, Executive Vice President from August 2019 to current
- Amgen Inc, Principal Scientist from August 2001 to July 2019
- University of California at Berkeley, Postdoctoral fellow from July 1998 to July 2001

Abstract

KRAS^{G12C} has emerged as a promising target in the treatment of solid tumors. Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-“undruggable” target; however clinically viable inhibitors have yet to be identified. Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRAS^{G12C} to identify inhibitors suitable for clinical development. Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond. Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRAS^{G12C} inhibitor currently in phase I/II/III clinical trials.

SPEAKERS



Han-Joo Kim, Ph.D.
CEO, IMNEWRUN Biosciences Inc.

Bio-sketch

- [Present] CEO, IMNEWRUN Biosciences Inc.
- Director, Yuhan Corp. R&D Strategy & Partnering, Business Development, Biostatistics
- Associate Director, Eisai, Biostatistics
- Sr. Principle Scientist, Novartis, Biostatistics

Abstract

Despite the decades of significant drug development efforts spent for Alzheimer's Disease (AD), no disease modifying agent has been approved. While there has been a plethora of enhanced understanding in brain biology and drug discovery, a lack of an effective brain delivery technology is still the eminent reason precluding new effective therapeutics in AD. Biologic drugs do not cross the BBB, but may enter into CSF and this often is, by misconception taken as a surrogate for BBB penetration. For therapeutics antibodies targeting amyloid-beta which reduce plaque, it is well known that there is a positive correlation between dose and ARIA-E. This suggests that the mechanism of brain entry is via BBB disruption. This in turn results in significant lack of treatment compliance at high dose as seen in recent aducanumab phase 3 trials. Therefore, development of an effective BBB-delivery technology is prerequisite for new treatment in AD. In this talk, I will introduce the Transmab™ platform technology which has shown to increase substantially the brain exposure without diminishing the systemic PK profile over control antibody. Transmab™-based therapeutics for disease-modifying potential for the treatment of neurodegenerative disease will be discussed.

SPEAKERS



Ted Moon, J.D., MBA
*Managing Director, RM Global Partners,
Partner, RMGP Biopharma Fund*

Bio-sketch

- RM Global Partners, LLC; Managing Director (present)
- RMGP Biopharma fund, Partner (present)
- Rogosin Institute (NY-Presbyterian Hospital and Weill Cornell Medical College), Board Member (present)
- Roberts Mitani, LLC; Managing Director
- Value Added Investment, Director and in-house counsel

Abstract

Given the swift rise and rapid expansion of Korean biotech/medtech industry in a world of interconnected global market, investment bankers' role remains essential in creating synergistic values for biotech and medtech companies. It is desirable to understand certain IB's roles and to understand how to utilize them from biotech/medtech entrepreneurs' perspective.

Facilitating certain investment banking transactions such as M&A, global licensing, or strategic investment on the world stage requires qualitative and quantitative capabilities. A couple of case studies are selected to ensample how RM Global could assist clients in presenting technology, sharing insight, experience, network, processes and, most importantly, allowing management to remain fully engaged and focused on their core operational activities.

SPEAKERS



Stephen Lee, Ph.D., MBA

Director, J&J Innovation, Asia Pacific Innovation Center (APIC)

Bio-sketch

- [Present] J&J Innovation, Asia Pacific Innovation Center (APIC), Director, New Ventures, North Asia
- Kybora EM (formerly Torrey EM), MD, APAC
- Ventac Partners, Partner, APAC
- USPTO, Patent Examiner

Abstract

Innovation is the driving force behind our industry which ultimately feeds into better healthcare and quality of life. Under the J&J Innovation, a unique ecosystem has been created to help accelerate open innovation that addresses medical unmet need and better patient outcome.

SPEAKERS



Taejin Yoon, Ph.D.
Executive Officer, Yuhan Corporation

Bio-sketch

- Yuhan Corporation, Head of Global BD
- Yonsei University, Research Professor
- Stanford University, School of Medicine, Postdoc

Abstract

Many people presume that business development (BD) teams in the biopharma industry are mostly concerned with L/I and L/O activities. Nonetheless, global BD team at Yuhan are not limited to doing just the licensing work, but our team carries out other core projects such as establishing a corporate R&D strategy for global expansion, developing a new BD model and making investment decisions. All of these tasks requires open innovation and Yuhan is making every efforts to establish its global presence by utilizing its open innovation experiences and know-hows from the past 5-6 years.

SPEAKERS



Kyuho Han, Ph.D.
CEO, MEDIC Life Sciences

Bio-sketch

- Scientist/Entrepreneur with 18 years of experience in academia and biotech industries
- MEDIC Life Sciences, Co-founder & CEO (2020-Current)
- Postdoctoral fellow, Genetics, Stanford University (Prof. Michael Bassik, 2014-2020)
- Ph.D., Chemical & Systems Biology, Stanford University (Prof. Tobias Meyer, 2007-2014)
- Research associate, SNU (Prof. Sung Hee Baek, 2006-2007)
- B.S., Biological Sciences, KAIST (2000-2006)
- Research associate/Manufacturing team, WELGENE Inc. (2002-2005)

Abstract

Cancer immunotherapy has gained much attention in the last several years as it has led to complete remissions even in some late-stage cancer patients by exploiting the patients' own immune systems. However, while immuno-oncology (I/O) drugs have shown great efficacies against many liquid cancers, they have not worked well for most solid tumors. The response of patients to I/O drugs are extremely variable, which further limits the applicability of I/O drugs. To tackle these issues, MEDIC Life Sciences is performing CRISPR functional genomics in 3D solid tumor models (cancer organoids) to systematically identify novel immunotherapies for various solid tumors. In this talk, we will share some data from our early proof of concept (POC) studies where we identified a few promising novel I/O drug targets for triple-negative breast cancer (TNBC), which ultimately validated the detection power of our high-throughput I/O drug target discovery platform for novel immunotherapeutics.

SPEAKERS

Jongsun Park, Ph.D.
Chief Executive Officer, InfoBoss, Inc.

Bio-sketch

- Mar 2015 – Present | InfoBoss, Inc., Seoul, Korea, Chief Executive Officer
- Mar 2013 – Apr 2015 | Stronghold Technology, Inc., Seoul, Korea, Director of Research Institute, Stronghold Innovation Center
- Mar 2012 – Mar 2013 | Diagnostics, Inc., San Diego, USA, Vice President of Bioinformatics
- Apr 2011 – Feb 2012 | Personal Genomics Institute, Suwon, Korea, Principle Investigator

Abstract

Owing to diverse source of big data emerged recently, hug amount of data is available for being analyzed. However, biological data, which is heterogeneous and even not digitalized, crude data usually written in natural language, have not been analyzed due to technical limitations. InfoBoss Inc. have developed various relational databases for archiving, analyzing, and predicting these data with various algorithms including artificial intelligences. From both UIBR™, a relational database of utilization information of biological resources, and UIBR-AI™, a prediction engine for predicting novel plant species for specific utilization, we extracted novel targets (plants and compounds) for drug development. Consequently, plant genome sequences were sequenced and analyzed with GeIS™ for predicting secondary metabolites predicted by the MetaPre-AI™ and confirmed by the Meta-ISM™. Together with the prediction of mode of actions by MetaTarget™, we successfully developed the pipeline to subject these candidates to normal drug develop pipeline with plentiful information for establishing strategy of drug development. We hope that the six pipelines InfoBoss has prepared can be successfully applied for new drug development pipeline with high-throughput concept, InfoBoss High-throughput Method (IHM™) which can provide extremely high efficiency.

SPEAKERS



Ahryon Cho, Ph.D.

Director, Mirae Asset Venture Investment Co., Ltd.

Bio-sketch

- Mirae Asset Venture Investment Co., Ltd., Director
- Serving on the boards: Vyriad, Inc., Hummingbird Bioscience Holdings Pte. Ltd., PinotBio, Inc., Genome Opinion, Inc., Pharos iBio Co., Ltd.
- Yonsei University College of Medicine, Research Assistant Professor
- Stanford University School of Medicine, Post-doctoral scholar
- Princeton University, Ph.D. in Molecular Biology and Neuroscience

Abstract

Raising capital is an immediate challenge that first-time entrepreneurs or start-up founders encounter from day one of their companies or even before the actual inception. The more cash flows into life science sectors, the more critical it is to find investors who secure funding rounds and provide resources as long-term partners. Some cases about investors' roles in building a great life science company will be discussed.

SPEAKERS



Seyoung Moon, Ph.D.
Director, ES Investor, Co., Ltd.

Bio-sketch

- ES Investor, Co., Ltd., Director, VC Investment Team (2018 - present)
- Korea BIO, Deputy Director, Korea Bio-Economy Research Center
- Samsung Medical Center, Researcher
- Korea Institute of Science & Technology Evaluation and Planning, Associate Research Fellow

Abstract

Amid COVID-19, Biotech and Life Sciences sector in Korea has attracted vast amount of funding both in private and public stages. Abundant liquidity along with favorable listing procedure will likely continue for a while with little change spotted ahead. I will share some recent trends and perspectives on private financing in Biotech and Life Sciences sector, as well as how to find good investors.

KASBP-SF Committee

Hanjo Lim	President	<i>Genentech</i>
Sehyun Kim	President Designated	<i>ABL Bio</i>
Gayoung Jeong	1 st Vice President	<i>Bristol Myers Squibb</i>
Oh Kyu Yoon	2 nd Vice President	<i>Gilead</i>
Dongkyoon Kim	Science Director	<i>Atreca</i>
Joon Won Jeong	Finance Director	<i>Exelixis</i>
Hyun Yong Jin	Membership Director	<i>Genentech</i>
Seung Bum Kim	Public Relations Director	<i>Accelaron</i>
Joonhee Park	General Director	<i>Kite pharma</i>
Meena Choi	Career Development Director	<i>Genentech</i>
Sunghoon Ma	Councilor	<i>Exelixis</i>
Hyunjeong Joh	Councilor	<i>Eidos Therapeutics</i>